David Sinclair starts an oral reprogramming race after Life Biosciences dosed a glaucoma volunteer

Earlier this week, Life Biosciences announced it dosed its first volunteer, and the target is as specific as it gets: glaucoma. In the trial, an experimental treatment is injected straight into the eyeball with the goal of regenerating healthy nerves in the eye, aiming to treat a disease that can cause vision loss. That is the immediate story. The deeper story is what David Sinclair, Life Biosciences' chairman and cofounder, wants to do next if this approach can work beyond one condition.

Sinclair told MIT Technology Review's Antonio Regalado that he plans to test a “highly, highly confidential” oral reprogramming drug as part of a $101 million competition organized by the XPrize Foundation. In other words: while one trial is quietly running in the eye, he is already trying to scale the concept to whole-body rejuvenation. For investors, boards, and anyone allocating risk capital in biotech, that combination matters. It is not just another platform headline. It is a bid to turn a technology that is showing promise in mice into a repeatable, drug-like strategy that can be tested in humans.

Reprogramming is currently the buzziest aging strategy, and Life Biosciences is not the only player betting that the field has its next lever. The underlying concept is grounded in Nobel Prize-winning work showing that four genetic factors can turn an adult cell into a stem cell, which can then be encouraged to become other cell types. In plain English: instead of targeting one aging hallmark, the approach tries to push cells into a “younger” functional state. Some studies in mice suggest benefits across tissue healing, vision, and learning and memory. But mouse promise and human outcomes are not the same universe, and the source is explicit that researchers still do not know if reprogramming will work in people.

That uncertainty is partly why reprogramming is also a market psychology story. Aging biology is complicated because multiple processes change across many systems as we get older, and scientists have tried to categorize them. In 2013, a team published nine “hallmarks of aging.” Over time, the targets have shifted with evidence and enthusiasm. Telomere attrition, for example, was once all the rage because telomeres shorten when cells divide, leaving DNA vulnerable to damage. The investor and hype cycle around telomeres included Liz Parrish, CEO of BioViva, who injected herself with an experimental gene therapy in 2015 hoping to lengthen her telomeres. Then that particular excitement cooled. The article also notes Parrish continued with self-experimentation, calling herself “the most genetically modified person on Earth,” and includes a correction: the first experimental gene therapy was in 2015, not 2017.

Another hallmark, cellular senescence, became the center of attention next. Senescent cells stop dividing but do not die; instead, they enter a “zombie” state that secretes chemicals associated with harmful inflammation, and those cells gradually accumulate in many organs. The pitch was clean: periodically clear senescent cells. Mouse studies in 2011 suggested that could delay age-related conditions like cataracts and hunchback, with treated mice appearing younger. But when approaches similar to senolytics were tried in humans, results disappointed. Unity Biotechnology trialed a similar strategy in people with osteoarthritis and an age-related eye condition in the late 2010s and early 2020s, then laid off every employee in May last year and has since shuttered entirely. That is not proof that senolytics fail, the source is careful to say it does not mean senolytic drugs targeting “zombie cells” won’t work. It is proof that translating a compelling mechanism into durable clinical results is hard enough to break companies.

Reprogramming is thriving partly because it offers a different failure mode. Instead of clearing a problematic cell state, it tries to reset the cell. That is why capital has piled into the area. In 2021, Antonio Regalado reported the founding of Altos Labs to pursue reprogramming for rejuvenation, funded by billionaire Yuri Milner, reportedly also Jeff Bezos and others, to the tune of $3 billion, a previously unheard-of figure for a biotech startup. Other well-funded companies have since emerged. Retro Biosciences, for instance, is pursuing reprogramming (among other approaches) with an effort to add 10 years of healthy life; its launch was supported by $180 million from OpenAI’s Sam Altman, and last month Retro announced a $1.8 billion valuation. NewLimit, another billionaire-backed biotech exploring reprogramming, says it has promising results from research in mice and plans to trial a drug designed to rejuvenate the liver in people next year; it raised $435 million last week toward reaching that goal. Life Biosciences itself most recently secured $80 million to support its research.

Now layer the regulatory and program-design reality on top. Human trials are launching, but the source makes clear that the field does not know if the approach will work. That gap in knowledge is the risk that boards underwrite, and it affects everything from trial design to how executives communicate upside without overpromising. It also explains why Sinclair's “whole-body rejuvenation” plan is both ambitious and potentially destabilizing. An eye trial is a narrow clinical question with a clear endpoint. Whole-body rejuvenation raises more uncertainty, more safety questions, and more complexity in measuring benefit across organs. That is precisely why a $101 million competition is interesting. A prize structure can accelerate progress, attract attention, and force teams to move, but it also raises the visibility of failures.

For decision-makers watching this space, the strategic stake is simple. The aging field is moving from “which hallmark should we target?” toward “can we rewire cell identity at scale?” The first dose in a glaucoma trial, the shift from cellular senescence and telomere hype cycles, and the surge of billionaire-backed capital all point to a moment of reckoning. If reprogramming delivers even partial, durable effects in humans, it can rewrite how longevity medicine gets financed and regulated. If it disappoints, it could do what Unity Biotechnology did, only faster. Either way, reprogramming is no longer a niche idea. It is the current center of gravity for biotech risk-taking.